TVM Capital Healthcare Opens New Office in Riyadh, Saudi Arabia
TVM Capital Healthcare, a global specialist healthcare private equity firm operating in emerging markets, announced today the opening of a new office in the capital of the Kingdom of Saudi Arabia. The purpose of the new office is to advise the group and its portfolio companies as they grow their operational footprint in the Kingdom of Saudi Arabia (KSA), the largest market in the region.
Establishing this local office comes after TVM Capital Healthcare successfully expanded its portfolio company Cambridge Medical and Rehabilitation Center from the UAE to KSA in the year 2019. By establishing this new presence, TVM Capital Healthcare expands its global network already spanning the U.S., Europe, MENA, and Southeast Asia, adding local healthcare advisory and operating expertise to its international team. The local office presence shall focus on supporting portfolio companies financed by TVM Capital Healthcare’s growth capital funds to complement the region’s healthcare system, help fulfill the demand for currently underserved healthcare verticals, and improve access to quality healthcare services locally.
Orhan Osmansoy, Managing Partner of TVM Capital Healthcare and Director of the new office commented: “Saudi Arabia today provides excellent growth opportunities for the specialist healthcare sector, which is our key expertise. We have been active in Saudi Arabia for a long time, but our new presence in Riyadh enables us to expand and deepen our local relationships and interact even more closely with investors, regulators, our peers in the industry, and entrepreneurs in the Kingdom. Saudi Arabia is the economic powerhouse in the region, and we are looking forward to supporting the Government’s Health Sector Transformation Program as outlined in the Vision 2030.”
Othman Abahussein, Operating Partner at TVM Capital Healthcare, Director of the new office based in Riyadh, added: “The Health Sector Transformation Program aims to make the local health sector more comprehensive, effective and integrated, based on the health needs of the individual and society at large. I am looking forward to working with all stakeholders to bring top-notch healthcare solutions using our global presence and network, closer to patients and their families in our country.”
- Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
- Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
- Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
- Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
- Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more